MET and neoplasm: Although there are few reports on the treatment of OPRCC diseases, some researchers (13, 14) have reported that mesenchymal-epithelial transition factor (MET), as a receptor for hepatocyte growth factor (HGF), belongs to the tyrosine kinase-TK family, and the HGF/MET signaling pathway is involved in the growth, survival, proliferation, differentiation and cell migration of tumor cells in OPRCC diseases.